Simon Ward
Directeur Général chez Incanthera Research & Development Ltd.
Fortune : 496 400 $ au 30/04/2024
Profil
Simon Julian Ward is the founder of York Pharma (R&D) Ltd.
He currently holds multiple CEO and Director positions at Incanthera Research & Development Ltd., Incanthera Plc, Incanthera Therapeutics Ltd., Spear Therapeutics Ltd., and Incanthera Oncology Ltd.
He previously held positions as Deputy Chairman at Medipex Ltd.
and Chief Scientific Officer at York Pharma Plc.
Ward holds a doctorate from the University of Oxford and a graduate degree from the London School of Hygiene & Tropical Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
Incanthera Plc
 Incanthera Plc Pharmaceuticals: MajorHealth Technology Incanthera Plc operates as a holding company, which focuses on drug discovery and development of targeted medicines for the treatment of cancer. The firm products include Sol, EP0015, Equin & Duo-C. The company was founded on March 2, 2010 and is headquartered in Manchester, the United Kingdom. 3,09% | 23/08/2023 | 3 064 199 ( 3,09% ) | 496 400 $ | 30/04/2024 |
Postes actifs de Simon Ward
| Sociétés | Poste | Début |
|---|---|---|
Incanthera Research & Development Ltd.
 Incanthera Research & Development Ltd. Medical DistributorsDistribution Services Incanthera Research & Development Ltd. develops drug delivery solutions for solid tumor chemotherapy. It offers cancer therapies, such as ICT01-2588, a vascular disrupting agent and drug delivery platform for lung and prostate cancer; and ICT03-Es5, a bioreductive anticancer agent for lung, liver, and breast cancer. The company was founded by Alan McGowan, Paul Loadman, Laurence Patterson, Andrew John Michael Duley, John Anthony Hadfield, Robert Falconer, and Jason Gill in 2010 and is headquartered in Manchester, the United Kingdom. | Directeur Général | 01/01/2010 |
Spear Therapeutics Ltd.
 Spear Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Spear Therapeutics Ltd. develops cancer treatment drugs. The firm offers cytochrome P450 (CYP)-activated prodrugs. It designs prodrugs that are activated by enzymes that are found in cancer tissues. The company was founded by Steven A. Everett and Gerard Andrew Potter and is headquartered in Manchester, the United Kingdom. | Directeur/Membre du Conseil | - |
Incanthera Plc
Incanthera Plc Pharmaceuticals: MajorHealth Technology Incanthera Plc operates as a holding company, which focuses on drug discovery and development of targeted medicines for the treatment of cancer. The firm products include Sol, EP0015, Equin & Duo-C. The company was founded on March 2, 2010 and is headquartered in Manchester, the United Kingdom. | Directeur Général | 23/10/2017 |
Incanthera Oncology Ltd.
 Incanthera Oncology Ltd. Medical DistributorsDistribution Services Incanthera Oncology Ltd. engages in the provision of drug development services. The company was founded on April 7, 2011 and is headquartered in Manchester, the United kingdom. | Directeur/Membre du Conseil | 10/01/2014 |
| Incanthera Therapeutics Ltd. | Directeur Général | 12/12/2014 |
Anciens postes connus de Simon Ward
| Sociétés | Poste | Fin |
|---|---|---|
York Pharma (R&D) Ltd.
 York Pharma (R&D) Ltd. Pharmaceuticals: MajorHealth Technology York Pharma (R&D) Ltd. manufactures pharmaceutical products. It is primarily concerned with developing solutions for skin diseases including psoriasis, eczema, cancer, and photo ageing. The company provides therapeutic strategies from new drug discovery to improved methods of diagnosis and novel delivery mechanisms. The company was founded in 2003 and is headquartered in Milton Keynes, GB. | Fondateur | - |
Medipex Ltd.
 Medipex Ltd. Miscellaneous Commercial ServicesCommercial Services Medipex Ltd. provides technology and knowledge transfer services to the National Health Service. It provides a range of services to NHS organizations to help them identify, protect and commercialize Intellectual Property owned by them through the work of their employees. The company was founded in 2002 and is headquartered in Leeds, the United Kingdom. | Directeur/Membre du Conseil | - |
York Pharma Plc
 York Pharma Plc Pharmaceuticals: MajorHealth Technology York Pharma Plc activity is acquiring, developing and commercialising prescription dermatological products. It focuses on a dermatological product called abafungin, a topical therapy intended for the treatment of fungal infections and some mixed microbial infections. The Group's product will be marketed under the trade mark Abasol. The Group's other product brands are Sabarep and Vampex. The Group operates in the United Kingdom, Japan and Germany. | Directeur Technique/Scientifique/R&D | - |
Formation de Simon Ward
| University of Oxford | Doctorate Degree |
| London School of Hygiene & Tropical Medicine | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
 | Health Technology |
| Entreprise privées | 7 |
|---|---|
York Pharma Plc
York Pharma Plc Pharmaceuticals: MajorHealth Technology York Pharma Plc activity is acquiring, developing and commercialising prescription dermatological products. It focuses on a dermatological product called abafungin, a topical therapy intended for the treatment of fungal infections and some mixed microbial infections. The Group's product will be marketed under the trade mark Abasol. The Group's other product brands are Sabarep and Vampex. The Group operates in the United Kingdom, Japan and Germany. | Health Technology |
York Pharma (R&D) Ltd.
York Pharma (R&D) Ltd. Pharmaceuticals: MajorHealth Technology York Pharma (R&D) Ltd. manufactures pharmaceutical products. It is primarily concerned with developing solutions for skin diseases including psoriasis, eczema, cancer, and photo ageing. The company provides therapeutic strategies from new drug discovery to improved methods of diagnosis and novel delivery mechanisms. The company was founded in 2003 and is headquartered in Milton Keynes, GB. | Health Technology |
Medipex Ltd.
Medipex Ltd. Miscellaneous Commercial ServicesCommercial Services Medipex Ltd. provides technology and knowledge transfer services to the National Health Service. It provides a range of services to NHS organizations to help them identify, protect and commercialize Intellectual Property owned by them through the work of their employees. The company was founded in 2002 and is headquartered in Leeds, the United Kingdom. | Commercial Services |
Spear Therapeutics Ltd.
Spear Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Spear Therapeutics Ltd. develops cancer treatment drugs. The firm offers cytochrome P450 (CYP)-activated prodrugs. It designs prodrugs that are activated by enzymes that are found in cancer tissues. The company was founded by Steven A. Everett and Gerard Andrew Potter and is headquartered in Manchester, the United Kingdom. | Health Technology |
Incanthera Oncology Ltd.
Incanthera Oncology Ltd. Medical DistributorsDistribution Services Incanthera Oncology Ltd. engages in the provision of drug development services. The company was founded on April 7, 2011 and is headquartered in Manchester, the United kingdom. | Distribution Services |
Incanthera Research & Development Ltd.
Incanthera Research & Development Ltd. Medical DistributorsDistribution Services Incanthera Research & Development Ltd. develops drug delivery solutions for solid tumor chemotherapy. It offers cancer therapies, such as ICT01-2588, a vascular disrupting agent and drug delivery platform for lung and prostate cancer; and ICT03-Es5, a bioreductive anticancer agent for lung, liver, and breast cancer. The company was founded by Alan McGowan, Paul Loadman, Laurence Patterson, Andrew John Michael Duley, John Anthony Hadfield, Robert Falconer, and Jason Gill in 2010 and is headquartered in Manchester, the United Kingdom. | Distribution Services |
| Incanthera Therapeutics Ltd. |